Mabs | www.gmachineinfo.com | 全球机械文献资源网

OA期刊

ISSN	1942-0862
刊名	Mabs
出版商	Taylor & Francis Inc.
url	https://www.tandfonline.com/loi/kmab20
机构	Taylor & Francis Ltd.

全部

2010	2011	2012	2013	2014	2015
2016	2017	2018	2019	2020	2021
2022	2023	2024	2025

2022, vol.14, no.1

题名

作者

出版年

年卷期

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors

Mohamed A.Alfaleh;Ayat Zawawi;Sawsan S.Al-Amri;Anwar M.Hashem;

2022

2022, vol.14, no.1

In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom

Line Ledsgaard;Andreas H.Laustsen;Urska Pus;Jack Wade;Pedro Villar;Kim Boddum;Peter Slavny;Edward W.Masters;Ana S.Arias;Saioa Oscoz;Daniel T.Griffiths;Alice M.Luther;Majken Lindholm;Rachael A.Leah;Marie Sofie Møller;Hanif Ali;John McCafferty;Bruno Lomonte;José M.Gutiérrez;Aneesh Karatt-Vellatt;

2022

2022, vol.14, no.1

Predicting antibody binders and generating synthetic antibodies using deep learning

Yoong Wearn Lim;Adam S.Adler;David S.Johnson;

2022

2022, vol.14, no.1

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

Monica L.Fernández-Quintero;Katharina B.Kroell;Lukas J.Grunewald;Anna-Lena M.Fischer;Jakob R.Riccabona;Klaus R.Liedl;

2022

2022, vol.14, no.1

Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics

Rahul Khetan;Robin Curtis;Charlotte M.Deane;Johannes Thorling Hadsund;Uddipan Kar;Konrad Krawczyk;Daisuke Kuroda;Sarah A.Robinson;Pietro Sormanni;Kouhei Tsumoto;Jim Warwicker;Andrew C.R.Martin;

2022

2022, vol.14, no.1

Reduction of therapeutic antibody self-association using yeast-display selections and machine learning

Emily K.Makowski;Hongwei Chen;Matthew Lambert;Eric M.Bennett;Nicole S.Eschmann;Yulei Zhang;Jennifer M.Zupancic;Alec A.Desai;Matthew D.Smith;Wenjia Lou;Amendra Fernando;Timothy Tully;Christopher J.Gallo;Laura Lin;Peter M.Tessier;

2022

2022, vol.14, no.1

Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

Jerome Egli;Stefan Heiler;Felix Weber;Guido Steiner;Timo Schwandt;Katharine Bray-French;Christian Klein;Sebastian Fenn;Gregor P.Lotz;Eugenia Opolka-Hoffmann;Thomas E.Kraft;Laetitia Petersen;Rebecca Moser;Jonathan DeGeer;Michel Siegel;Daniela Finke;Juliana Bessa;Antonio Iglesias;

2022

2022, vol.14, no.1

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation

Md Harunur Rashid;

2022

2022, vol.14, no.1

Investigating protein–excipient interactions of a multivalent VHH therapeutic protein using NMR spectroscopy

Jainik Panchal;Bradley T.Falk;Valentyn Antochshuk;Mark A.McCoy;

2022

2022, vol.14, no.1

Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names

Ian Wilkinson;Geoff Hale;

2022

2022, vol.14, no.1